{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:26:13Z","timestamp":1790641573610,"version":"4.1.0"},"reference-count":80,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The etiology of primary podocytopathies including childhood nephrotic syndrome, minimal change disease, primary FSGS as well as recurrent FSGS had long remained elusive. The development of robust anti-nephrin autoantibody detection methods, the identification of these antibodies in idiopathic nephrotic syndrome, and the demonstration of their causal role in podocytopathy have led to a paradigm shift in our understanding of these diseases, offering new insights into pathophysiology and promising improved diagnostic, prognostic, and therapeutic approaches. Prognostication and risk stratification on the basis of anti-nephrin antibody detection as well as personalized therapeutic strategies including therapies targeting antibody-producing B cells or even antigen-specific depletion of autoreactive B cells could markedly improve treatment outcomes and patient quality of life in the future. In this review, we explore the prevalence of anti-nephrin antibodies in various glomerular diseases, current treatment options for primary podocytopathies, and how the emerging evidence of anti-nephrin antibody-mediated podocytopathy could influence future treatment approaches for affected patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.0000001008","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T17:00:47Z","timestamp":1769014847000},"page":"1628-1637","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A New Hope for Treating Podocytopathies"],"prefix":"10.2215","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7000-6526","authenticated-orcid":false,"given":"Nastassia","family":"Liaukouskaya","sequence":"first","affiliation":[{"name":"III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Hamburg Center for Kidney Health, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4899-414X","authenticated-orcid":false,"given":"Felicitas E.","family":"Hengel","sequence":"additional","affiliation":[{"name":"III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Hamburg Center for Kidney Health, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"M\u00fchlig","sequence":"additional","affiliation":[{"name":"Hamburg Center for Kidney Health, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Department of Pediatric Nephrology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola M.","family":"Tomas","sequence":"additional","affiliation":[{"name":"III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Hamburg Center for Kidney Health, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7175-5062","authenticated-orcid":false,"given":"Tobias B.","family":"Huber","sequence":"additional","affiliation":[{"name":"III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Hamburg Center for Kidney Health, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"1","key":"B1-20260910","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S0140-6736(70)91905-7","article-title":"Pathology of the nephrotic syndrome in children: a report for the International Study of Kidney Disease in Children","volume":"760","author":"Churg","year":"1970","journal-title":"Lancet."},{"issue":"2","key":"B2-20260910","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/ki.1978.23","article-title":"Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children","volume":"13","year":"1978","journal-title":"Kidney Int."},{"issue":"3","key":"B3-20260910","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2215\/CJN.03531006","article-title":"Adult minimal-change disease: clinical characteristics, treatment, and outcomes","volume":"2","author":"Waldman","year":"2007","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"B4-20260910","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.akdh.2024.02.002","article-title":"Minimal change disease","volume":"31","author":"Gomez","year":"2024","journal-title":"Adv Kidney Dis Health."},{"issue":"4 suppl","key":"B5-20260910","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"issue":"6","key":"B6-20260910","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jpeds.2009.12.020","article-title":"Time for initial response to steroids is a major prognostic factor in idiopathic nephrotic syndrome","volume":"156","author":"Vivarelli","year":"2010","journal-title":"J Pediatr."},{"issue":"17","key":"B7-20260910","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1056\/NEJMc1202500","article-title":"Resolution of recurrent focal segmental glomerulosclerosis after retransplantation","volume":"366","author":"Gallon","year":"2012","journal-title":"N Engl J Med."},{"issue":"1","key":"B8-20260910","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1038\/s41467-023-43504-8","article-title":"The extrafollicular B cell response is a hallmark of childhood idiopathic nephrotic syndrome","volume":"14","author":"Al-Aubodah","year":"2023","journal-title":"Nat Commun."},{"issue":"7880","key":"B9-20260910","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0140-6736(74)91880-7","article-title":"Pathogenesis of lipoid nephrosis: a disorder of T-cell function","volume":"2","author":"Shalhoub","year":"1974","journal-title":"Lancet."},{"issue":"1","key":"B10-20260910","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1681\/ASN.2021060794","article-title":"Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology","volume":"33","author":"Watts","year":"2022","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"B11-20260910","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa2314471","article-title":"Autoantibodies targeting nephrin in podocytopathies","volume":"391","author":"Hengel","year":"2024","journal-title":"N Engl J Med."},{"issue":"5","key":"B12-20260910","doi-asserted-by":"crossref","first-page":"e186769","DOI":"10.1172\/JCI186769","article-title":"Passive transfer of patient-derived anti-nephrin autoantibodies causes a podocytopathy with minimal change lesions","volume":"135","author":"Hengel","year":"2025","journal-title":"J Clin Invest."},{"key":"B13-20260910","article-title":"Evaluation of methodologies in anti-nephrin autoantibody detection","author":"Liu","year":"2024","journal-title":"bioRxiv."},{"issue":"5","key":"B14-20260910","doi-asserted-by":"crossref","first-page":"sfaf100","DOI":"10.1093\/ckj\/sfaf100","article-title":"Potential and pitfalls of measuring circulating anti-nephrin autoantibodies in glomerular diseases","volume":"18","author":"Hengel","year":"2025","journal-title":"Clin Kidney J."},{"issue":"14","key":"B15-20260910","first-page":"1366","article-title":"Autoantibodies targeting nephrin in podocytopathies","volume":"391","author":"Bruschi","year":"2024","journal-title":"N Engl J Med."},{"issue":"10S","key":"B16-20260910","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1681\/ASN.2024asgm7c03","article-title":"Host-cell line origin of recombinant human nephrin impacts anti-nephrin antibody enzyme-linked immunosorbent assay (ELISA): insights into glycan-mediated discrepancy: FR-OR87","volume":"35","author":"Ghasemi","year":"2024","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"B17-20260910","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.kint.2025.01.003","article-title":"Reevaluating anti-nephrin autoantibodies by ELISA using human embryonic kidney\u2013derived recombinant extracellular domain of human nephrin","volume":"107","author":"Shirai","year":"2025","journal-title":"Kidney Int."},{"issue":"5","key":"B18-20260910","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1056\/NEJMe2404974","article-title":"Kidney disease and antinephrin antibodies","volume":"391","author":"Reiser","year":"2024","journal-title":"N Engl J Med."},{"issue":"6","key":"B19-20260910","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.kint.2024.09.006","article-title":"Anti-slit diaphragm antibodies on kidney biopsy identify pediatric patients with steroid-resistant nephrotic syndrome responsive to second-line immunosuppressants","volume":"106","author":"Raglianti","year":"2024","journal-title":"Kidney Int."},{"issue":"6","key":"B20-20260910","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.kint.2025.01.019","article-title":"Anti-nephrin autoantibodies in steroid-resistant nephrotic syndrome may inform treatment strategy","volume":"107","author":"Hengel","year":"2025","journal-title":"Kidney Int."},{"issue":"3","key":"B21-20260910","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.kint.2023.11.022","article-title":"A multi-institutional study found a possible role of anti-nephrin antibodies in post-transplant focal segmental glomerulosclerosis recurrence","volume":"105","author":"Shirai","year":"2024","journal-title":"Kidney Int."},{"issue":"4","key":"B22-20260910","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.kint.2024.07.022","article-title":"Pre-transplant anti-nephrin antibodies are specific predictors of recurrent diffuse podocytopathy in the kidney allograft","volume":"106","author":"Batal","year":"2024","journal-title":"Kidney Int."},{"issue":"1","key":"B23-20260910","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41572-020-0196-7","article-title":"Podocytopathies","volume":"6","author":"Kopp","year":"2020","journal-title":"Nat Rev Dis Primers."},{"issue":"10","key":"B24-20260910","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1111\/ajt.17077","article-title":"Circulating nephrin autoantibodies and posttransplant recurrence of primary focal segmental glomerulosclerosis","volume":"22","author":"Hattori","year":"2022","journal-title":"Am J Transplant."},{"issue":"5","key":"B25-20260910","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1172\/JCI27414","article-title":"Nephrin ectodomain engagement results in Src kinase activation, nephrin phosphorylation, Nck recruitment, and actin polymerization","volume":"116","author":"Verma","year":"2006","journal-title":"J Clin Invest."},{"key":"B26-20260910","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3389\/fendo.2018.00302","article-title":"Nephrin signaling in the podocyte: an updated view of signal regulation at the slit diaphragm and beyond","volume":"9","author":"Martin","year":"2018","journal-title":"Front Endocrinol."},{"issue":"1","key":"B27-20260910","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1681\/ASN.2017030285","article-title":"ShcA adaptor protein promotes nephrin endocytosis and is upregulated in proteinuric nephropathies","volume":"29","author":"Martin","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"B28-20260910","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1046\/j.1523-1755.2003.00097.x","article-title":"Clustering-induced tyrosine phosphorylation of nephrin by Src family kinases","volume":"64","author":"Lahdenper\u00e4","year":"2003","journal-title":"Kidney Int."},{"issue":"3","key":"B29-20260910","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1074\/jbc.M112.439463","article-title":"Direct regulation of nephrin tyrosine phosphorylation by Nck adaptor proteins","volume":"288","author":"New","year":"2013","journal-title":"J Biol Chem."},{"issue":"12","key":"B30-20260910","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1097\/01.ASN.0000146689.88078.80","article-title":"SRC-family kinase Fyn phosphorylates the cytoplasmic domain of nephrin and modulates its interaction with podocin","volume":"15","author":"Li","year":"2004","journal-title":"J Am Soc Nephrol."},{"issue":"45","key":"B31-20260910","doi-asserted-by":"crossref","first-page":"41543","DOI":"10.1074\/jbc.C100452200","article-title":"Interaction with podocin facilitates nephrin signaling","volume":"276","author":"Huber","year":"2001","journal-title":"J Biol Chem."},{"issue":"14","key":"B32-20260910","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1128\/MCB.23.14.4917-4928.2003","article-title":"Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling","volume":"23","author":"Huber","year":"2003","journal-title":"Mol Cell Biol."},{"issue":"5","key":"B33-20260910","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1172\/JCI27400","article-title":"Bigenic mouse models of focal segmental glomerulosclerosis involving pairwise interaction of CD2AP, Fyn, and synaptopodin","volume":"116","author":"Huber","year":"2006","journal-title":"J Clin Invest."},{"issue":"46","key":"B34-20260910","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0607465103","article-title":"Podocin and MEC-2 bind cholesterol to regulate the activity of associated ion channels","volume":"103","author":"Huber","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"9","key":"B35-20260910","doi-asserted-by":"crossref","first-page":"e86177","DOI":"10.1172\/jci.insight.86177","article-title":"A flexible, multilayered protein scaffold maintains the slit in between glomerular podocytes","volume":"1","author":"Grahammer","year":"2016","journal-title":"JCI Insight."},{"issue":"1","key":"B36-20260910","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1038\/s41467-022-33748-1","article-title":"A slit-diaphragm-associated protein network for dynamic control of renal filtration","volume":"13","author":"Kocylowski","year":"2022","journal-title":"Nat Commun."},{"issue":"1","key":"B37-20260910","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41467-023-36068-0","article-title":"The classical pathway triggers pathogenic complement activation in membranous nephropathy","volume":"14","author":"Seifert","year":"2023","journal-title":"Nat Commun."},{"issue":"3","key":"B38-20260910","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1053\/j.ajkd.2015.07.006","article-title":"AJKD atlas of renal pathology: membranous nephropathy","volume":"66","author":"Fogo","year":"2015","journal-title":"Am J Kidney Dis."},{"issue":"4","key":"B39-20260910","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2011.06.004","article-title":"Idiopathic membranous nephropathy: an autoimmune disease","volume":"31","author":"Makker","year":"2011","journal-title":"Semin Nephrol."},{"issue":"1","key":"B40-20260910","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med."},{"issue":"24","key":"B41-20260910","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med."},{"issue":"5","key":"B42-20260910","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1681\/ASN.2017070805","article-title":"The Most N-Terminal region of THSD7A is the predominant target for autoimmunity in THSD7A-Associated membranous nephropathy","volume":"29","author":"Seifert","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B43-20260910","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.kint.2020.09.016","article-title":"Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis","volume":"100","author":"Caza","year":"2021","journal-title":"Kidney Int."},{"issue":"1","key":"B44-20260910","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int."},{"issue":"5","key":"B45-20260910","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1681\/ASN.2020081165","article-title":"Protocadherin 7-Associated membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J Am Soc Nephrol."},{"issue":"7","key":"B46-20260910","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1681\/ASN.2020101395","article-title":"Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy","volume":"32","author":"Al-Rabadi","year":"2021","journal-title":"J Am Soc Nephrol."},{"issue":"26","key":"B47-20260910","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa012895","article-title":"Antenatal membranous glomerulonephritis due to anti\u2013neutral endopeptidase antibodies","volume":"346","author":"Debiec","year":"2002","journal-title":"N Engl J Med."},{"issue":"10","key":"B48-20260910","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1681\/ASN.2022050608","article-title":"Netrin G1 is a novel target antigen in primary membranous nephropathy","volume":"33","author":"Reinhard","year":"2022","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B49-20260910","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/s41467-023-37836-8","article-title":"Non-functional ubiquitin C-terminal hydrolase L1 drives podocyte injury through impairing proteasomes in autoimmune glomerulonephritis","volume":"14","author":"Reichelt","year":"2023","journal-title":"Nat Commun."},{"issue":"S4","key":"B50-20260910","doi-asserted-by":"crossref","first-page":"68","DOI":"10.33594\/000000432","article-title":"The intertwining of autophagy and the ubiquitin proteasome system in podocyte (Patho)Physiology","volume":"55","author":"Heintz","year":"2021","journal-title":"Cell Physiol Biochem."},{"issue":"5","key":"B51-20260910","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","article-title":"Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int."},{"issue":"1","key":"B52-20260910","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.kint.2023.09.001","article-title":"Executive summary of the KDIGO 2024 clinical practice guideline for the management of lupus nephritis","volume":"105","author":"Rovin","year":"2024","journal-title":"Kidney Int."},{"issue":"8","key":"B53-20260910","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.ekir.2025.05.005","article-title":"Non-invasive diagnosis of anti-nephrin\u2013associated podocytopathy","volume":"10","author":"Hengel","year":"2025","journal-title":"Kidney Int Rep."},{"issue":"4","key":"B54-20260910","first-page":"291","article-title":"Minimal-change glomerulopathy of adulthood","volume":"8","author":"Korbet","year":"1988","journal-title":"Am J Nephrol."},{"issue":"11","key":"B55-20260910","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1093\/ndt\/11.11.2192","article-title":"Long-term outcome of adult-onset minimal-change nephropathy","volume":"11","author":"Mak","year":"1996","journal-title":"Nephrol Dial Transplant."},{"issue":"3","key":"B56-20260910","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1053\/ajkd.2002.31400","article-title":"Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome","volume":"39","author":"Nakayama","year":"2002","journal-title":"Am J Kidney Dis."},{"issue":"7","key":"B57-20260910","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ndt\/gfg134","article-title":"Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses","volume":"18","author":"Tse","year":"2003","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"B58-20260910","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2215\/CJN.06180519","article-title":"Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: a multicenter, randomized, controlled Trial","volume":"15","author":"Medjeral-Thomas","year":"2020","journal-title":"Clin J Am Soc Nephrol."},{"issue":"2","key":"B60-20260910","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1542\/peds.2008-1559","article-title":"Management of childhood onset nephrotic syndrome","volume":"124","author":"Gipson","year":"2009","journal-title":"Pediatrics."},{"issue":"11","key":"B61-20260910","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1007\/s00467-009-1282-y","article-title":"Management patterns of childhood-onset nephrotic syndrome","volume":"24","author":"MacHardy","year":"2009","journal-title":"Pediatr Nephrol."},{"key":"B62-20260910","doi-asserted-by":"crossref","DOI":"10.1016\/j.ekir.2026.103794","article-title":"Effect of steroids on antinephrin autoantibodies and B cells in minimal change disease","author":"Hengel","year":"2026","journal-title":"Kidney Int Rep."},{"key":"B63-20260910","article-title":"Initial treatment of idiopathic steroid-sensitive nephrotic syndrome in children: a randomised, controlled, non-inferiority trial comparing mycophenolate mofetil and prednisone (INTENT Study) \u2013 By the German society for paediatric nephrology","author":"Benz","year":"2025","journal-title":"Soc Sci Res Netw."},{"issue":"7","key":"B64-20260910","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1093\/ndt\/gfm128","article-title":"Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome?","volume":"22","author":"Hofstra","year":"2007","journal-title":"Nephrol Dial Transplant."},{"issue":"7","key":"B65-20260910","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","article-title":"Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy","volume":"19","author":"Benz","year":"2004","journal-title":"Pediatr Nephrol."},{"issue":"10","key":"B66-20260910","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/ndt\/gfaa133","article-title":"Comparison of treatment options in adults with frequently relapsing or steroid-dependent minimal change disease","volume":"36","author":"Heybeli","year":"2021","journal-title":"Nephrol Dial Transplant."},{"issue":"3","key":"B67-20260910","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/ki.2012.444","article-title":"Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease","volume":"83","author":"Munyentwali","year":"2013","journal-title":"Kidney Int."},{"issue":"48","key":"B68-20260910","doi-asserted-by":"crossref","first-page":"28799","DOI":"10.18632\/oncotarget.25612","article-title":"Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome","volume":"9","author":"Fenoglio","year":"2018","journal-title":"Oncotarget."},{"issue":"5","key":"B69-20260910","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ekir.2023.02.1070","article-title":"Rituximab as initial therapy in adult patients with minimal change disease","volume":"8","author":"Guan","year":"2023","journal-title":"Kidney Int Rep."},{"issue":"1","key":"B70-20260910","doi-asserted-by":"crossref","first-page":"sfae348","DOI":"10.1093\/ckj\/sfae348","article-title":"Rituximab as a first-line therapy in children with new-onset idiopathic nephrotic syndrome","volume":"18","author":"Zhang","year":"2025","journal-title":"Clin Kidney J."},{"issue":"85","key":"B71-20260910","doi-asserted-by":"crossref","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","article-title":"Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis","volume":"3","author":"Fornoni","year":"2011","journal-title":"Sci Transl Med."},{"issue":"8","key":"B72-20260910","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.ekir.2022.05.024","article-title":"The role of rituximab in primary focal segmental glomerular sclerosis of the adult","volume":"7","author":"Tedesco","year":"2022","journal-title":"Kidney Int Rep."},{"issue":"4","key":"B73-20260910","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ajt.2023.12.010","article-title":"Efficacy of combined rituximab and daratumumab treatment in posttransplant recurrent focal segmental glomerulosclerosis","volume":"24","author":"Angeletti","year":"2024","journal-title":"Am J Transplant."},{"issue":"2","key":"B74-20260910","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2215\/CJN.08970719","article-title":"Recurrence of FSGS after kidney transplantation in adults","volume":"15","author":"Uffing","year":"2020","journal-title":"Clin J Am Soc Nephrol."},{"key":"B75-20260910","doi-asserted-by":"crossref","first-page":"1167741","DOI":"10.3389\/fimmu.2023.1167741","article-title":"State of the art in childhood nephrotic syndrome: concrete discoveries and unmet needs","volume":"14","author":"Vincenti","year":"2023","journal-title":"Front Immunol."},{"issue":"4","key":"B76-20260910","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1681\/ASN.0000000642","article-title":"Anti-slit antibodies against podocin and Kirrel1 in pediatric and adult podocytopathies","volume":"36","author":"Raglianti","year":"2025","journal-title":"J Am Soc Nephrol."},{"key":"B77-20260910","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jaut.2017.12.014","article-title":"Autoantibodies against podocytic UCHL1 are associated with idiopathic nephrotic syndrome relapses and induce proteinuria in mice","volume":"89","author":"Jamin","year":"2018","journal-title":"J Autoimmun."},{"key":"B78-20260910","doi-asserted-by":"crossref","first-page":"822508","DOI":"10.3389\/fimmu.2022.822508","article-title":"Strategies towards antigen-specific treatments for membranous nephropathy","volume":"13","author":"K\u00f6llner","year":"2022","journal-title":"Front Immunol."},{"issue":"4","key":"B79-20260910","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.kint.2024.01.021","article-title":"An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells","volume":"105","author":"Seifert","year":"2024","journal-title":"Kidney Int."},{"issue":"6","key":"B80-20260910","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol."},{"issue":"2","key":"B81-20260910","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/ndt\/gfae165","article-title":"CAAR NK and T cells to eliminate autoreactive lymphocytes in autoimmune disorders","volume":"40","author":"Seifert","year":"2025","journal-title":"Nephrol Dial Transplant."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:00:56Z","timestamp":1789056056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001008"}},"subtitle":["Emerging Role of Anti-Nephrin Antibody"],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":80,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000001008","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]}}}